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PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of 
development for non-small cell lung cancer (NSCLC)
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Toll-like receptors (TLRs) play a key role in the human immune system 
by recognizing speciﬁc molecular patterns in invading pathogens and 
driving appropriate immune responses. TLR9 recognizes unmethylated 
cytosine-guanine (CpG) motifs that are common in viral and bacterial 
DNA. Human TLR9 is expressed in plasmacytoid dendritic cells and 
B-lymphocytes and activation by CpG motifs in viral or bacterial DNA 
triggers a cascade of immune events leading to both innate and adap-
tive immune responses.
PF-3512676, a synthetic, single-stranded, phosphorothioate oligode-
oxynucleotide that contains unmethylated CpG motifs, is a pharmaco-
logic agonist of human TLR9 that can drive Th1 innate and adaptive 
immune responses. In addition to targeting invading pathogens, these 
immune responses can potentially be directed against tumor-associated 
antigens (TAAs) and provide antitumor activity in cancer patients.
PF-3512676 monotherapy has demonstrated antitumor activity in 
several murine cancer models, although the activity is more limited in 
large, established tumors than in smaller tumors. In the treatment of 
large, established tumors, the addition of PF-3512676 to other forms 
of anticancer therapy (chemotherapy, monoclonal antibodies, radia-
tion therapy, or surgery) has produced additive or synergistic efﬁcacy. 
Both innate and adaptive immune responses are potentially relevant to 
the activity of PF-3512676, and T-cell memory responses have been 
demonstrated based on tumor rejection following rechallenge in PF-
3512676-cured animals.
In phase 1 and 2 clinical trials sponsored by Coley Pharmaceutical 
Group, single-agent subcutaneous PF-3512676 demonstrated activity in 
patients with advanced malignant melanoma, advanced renal cell carci-
noma, and relapsed or refractory cutaneous T-cell lymphoma. In phase 
1 trials, PF-3512676 was safely combined with rituximab in patients 
with non-Hodgkin’s lymphoma and with trastuzumab in patients with 
metastatic breast cancer.
In a randomized phase 2 trial investigating the addition of PF-3512676 
to taxane/platinum doublet chemotherapy in chemonaive patients with 
Stage IIIB or IV NSCLC, a higher objective response rate and a trend 
toward improved survival was reported for patients treated with PF-
3512676. The adverse event proﬁle for the combination arm of the trial 
was acceptable-the addition of PF-3512676 was not associated with 
clinically meaningful additional toxicity.
Pﬁzer is continuing the development of PF-3512676 for the treatment 
of advanced NSCLC with:
• Two pivotal, randomized, phase 3 registration trials in combina-
tion with platinum-based chemotherapy (paclitaxel/carboplatin or 
gemcitabine/cisplatin) in chemonaive patients with Stage IIIB/IV 
NSCLC of any histologic subtype
• A randomized phase 2 trial in combination with paclitaxel/carbo-
platin/bevacizumab in chemonaive patients with Stage IIIB/IV non-
squamous NSCLC
• Two randomized phase 2 trials in combination with pemetrexed 
or erlotinib in patients with previously treated locally advanced or 
metastatic NSCLC
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Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in 
patients with advanced bronchioloalveolar carcinoma (BAC): a 
Southwest Oncology Group Study (S0310).
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Background: Granulocyte macrophage-colony stimulating fac-
tor (GM-CSF) gene-modiﬁed, irradiated, whole tumor cell vaccines 
(GVAX(r)) have been shown to induce antitumor immunity against 
multiple cancers. Based on successful vaccine production and promis-
ing efﬁcacy in patients with advanced BAC in earlier studies a phase 
II trial of CG8123 (GVAX) in patients (pts) with advanced BAC was 
performed. 
Methods: 18 eligible pts with good performance status (0/1) and stage 
IIIB/IV BAC (BAC, adenocarcinoma with BAC and its variants) were 
accrued. Pts underwent surgery to obtain tumor tissue for autologous 
vaccine production. 9 eligible pts received vaccine via intradermal 
injections (every 2 weeks x 5). 6 pts did not receive vaccine: 4 inad-
equate vaccine produced, 1 died prior to receiving vaccine, one went 
off study due to symptomatic deterioration but received vaccine on 
compassionate use off protocol. 3 pts were ineligible for vaccine after 
tumor harvest: 2 pathology inconsistent with BAC and 1 due to disease 
progression.
Results: Pt characteristics: Median age: 63 years (range 40-73); Sex 
M/F = 5/13; previously treated/untreated = 14/4; nodular pattern/dif-
fuse pattern = 14/4. There were no RECIST criteria responses. With a 
median follow-up of 19 months, median progression free survival is 5 
months and median survival is 10 months. The most common vac-
cine related toxicities were grade 2 injection site reaction and fatigue. 
Tumor volumetric analysis will be performed using computer assisted 
image analysis (CAIA). Ongoing correlative studies are examining 
biomarkers and immunological markers. Although the planned sample 
size was 117 patients, accrual was halted at the request of the vaccine 
manufacturer (Cell Genesys). 
Conclusions: Although the sample size was limited there was no evi-
dence of anti-tumor activity utilizing the autologous vaccine, CG8123 
(GVAX), in pts with advanced BAC. The vaccine was associated with 
minimal side effects. The burden of disease in most patients enrolled 
was signiﬁcant and may have inﬂuenced the likelihood of beneﬁt, sug-
gesting that this therapeutic approach may be better suited for evalua-
tion in patients with minimal tumor burden or in the adjuvant setting. 
Due to the challenges of an autologous vaccine platform and lack of 
anti-tumor activity CG8123 (GVAX) will not be further developed in 
NSCLC.
